<DOC>
	<DOCNO>NCT01097057</DOCNO>
	<brief_summary>This phase II trial study well give rituximab ; ifosfamide , carboplatin , etoposide ( ICE ) combination chemotherapy ; filgrastim ( G-CSF ) together plerixafor work treat patient non-Hodgkin lymphoma undergoing mobilization autologous peripheral blood stem cell . Giving chemotherapy ( ICE ) monoclonal antibody , rituximab , stop growth cancer cell stop divide kill help get well autologous stem cell product . Giving colony-stimulating factor , G-CSF , plerixafor help stem cell move patient 's bone marrow blood collect stored future autologous transplant .</brief_summary>
	<brief_title>Rituximab , Combination Chemotherapy , Filgrastim ( G-CSF ) , Plerixafor Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization Autologous Peripheral Blood Stem Cells</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy combine RICE ( rituximab-ifosfamide-carboplatin-etoposide regimen [ R-ICE regimen ] ) , G-CSF , plerixafor collect autologous peripheral blood stem cell ( PBSC ) non-Hodgkin 's lymphoma ( NHL ) patient : number day apheresis required reach &gt; = 5 x 10^6 cluster differentiation ( CD ) 34 cells/kg total number CD34 cells/kg collect maximum 4 day &gt; = 5 x 10^6 CD34 cells/kg obtain . OUTLINE : Patients receive rituximab intravenously ( IV ) day 1 , etoposide IV day 2-4 , carboplatin IV day 3 , ifosfamide IV day 3 24 hour . Patients also receive filgrastim subcutaneously ( SC ) daily begin day 6 continue apheresis complete plerixafor SC daily 4 day begin 24 hour recovery nadir continue apheresis complete . Patients may undergo 4 apheresis procedure optimal number CD34+ cell collect . After completion study treatment , patient follow 30 day periodically 12 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Diagnosis CD20+ nonHodgkin 's lymphoma Left ventricular ejection fraction rest &gt; = 50 % demonstrate multi gated acquisition scan ( MUGA ) echocardiogram Bilirubin = &lt; 2.0 mg/dL ( except isolate hyperbilirubinemia attribute Gilbert syndrome ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 3 time upper limit normal Creatinine clearance ( calculated creatinine clearance permit ) &gt; 50 mL/min Signed informed consent Planned autologous transplant within 3 month collection peripheral blood stem cell ( PBSCs ) Karnofsky performance score &lt; 70 % Uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical improvement ) Prior malignancy except resect basal cell carcinoma treat cervical carcinoma breast cancer situ ; cancer treat curative intent &gt; 5 year previously allow Pregnant breastfeed Fertile men woman unwilling use contraceptive technique time chemomobilization Prior autologous allogeneic hematopoietic stem cell transplant ( HSCT ) Human immunodeficiency virus ( HIV ) positive Plan treat another investigational therapy within 4 week enrol study Hepatitis B carrier</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>